Pediatric melanoma is a rare but clinically distinct malignancy, accounting for 1–4% of all melanoma cases. It encompasses unique subtypes—Spitzoid melanoma, melanoma arising in congenital melanocytic nevi, and conventional melanoma—each with specific biological behavior and therapeutic implications. While surgical excision remains the primary treatment, systemic therapies are...
Introduction Dermatologic toxicities represent a broad and heterogeneous group of immune-related adverse events (irAEs) in patients with melanoma treated with immunotherapy, ranging from mild, transient, and self-limiting reactions to severe and potentially life-threatening conditions. Certain dermatologic toxicities have been shown to reflect immune system activation and may...
Introduction Chronic spontaneous urticaria (CSU) is a skin disorder for which short-course systemic corticosteroids are recommended only as rescue medication during acute exacerbations. Here, we describe real-world corticosteroid use, adverse events (AEs) occurring post-corticosteroid initiation, and health care resource utilization (HCRU) of patients with CSU in the USA. Methods...
Introduction A reliable, well-defined measure of fingernail psoriasis severity for clinical trials is an unmet need. The objective of this study was to develop and validate the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO), an illustrated 5-point tool for assessing nail psoriasis severity. Methods A global panel of dermatologists participated in concept...
Introduction HS-20137 is a novel interleukin-23 inhibitor and is suggested to be effective for the treatment of psoriasis in a phase 1b study. Our study aimed to evaluate the efficacy and safety of HS-20137 in patients with moderate-to-severe plaque psoriasis in a larger and longer phase 2 study. Methods This was a randomized, double-blind, placebo-controlled phase 2 study up to...
Introduction Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase (BTK) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of chronic spontaneous urticaria (CSU). Dupilumab, an interleukin-4 receptor-α monoclonal antibody, was approved by the FDA for CSU in early 2025. Here, we report the design of RECLAIM (NCT06868212), a...
Introduction Mild-to-moderate scalp seborrheic dermatitis (SD) is commonly managed by using anti-SD shampoos containing antifungal, anti-inflammatory, and keratolytic agents. A newly formulated anti-SD shampoo containing the patented combination of two antifungal actives has shown good clinical efficacy and tolerability in a previous two-phase randomized controlled trial. Methods...
Introduction Long-term disease and symptom control is a goal of atopic dermatitis (AD) therapy. This study assessed the long-term maintenance of disease and symptom control with as-needed application of ruxolitinib cream. Methods Patients aged ≥ 12 years with AD, an Investigator’s Global Assessment (IGA) score of 2/3, and 3–20% affected body surface area were included in the...
Introduction Management of atrophic acne scars remains challenging, and conventional treatments often yield suboptimal or inconsistent outcomes. Stromal vascular fraction (SVF), a cell-rich fraction derived from adipose tissue, has recently gained attention as a promising regenerative therapy. Several previous studies have reported benefits of SVF when combined with other...
Introduction Despite the expanding range of approved systemic therapies for atopic dermatitis (AD) and psoriasis (PSO), data on patient preferences remain limited. It is largely unknown whether patients wish to initiate systemic treatment, which route of administration (oral versus subcutaneous) they prefer, or what factors drive their treatment preferences. This study evaluated...
Psoriasis is a chronic inflammatory skin disease characterized by well-demarcated erythematous plaques with silvery scales that affects 2–3% of the global population. Beyond its dermatological manifestations, psoriasis has recently been recognised as a significant cardiovascular risk factor, patients with psoriasis have an approximately 50% increased relative risk of major...
Introduction Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease frequently associated with other immune-mediated inflammatory diseases (IMIDs), such as systemic lupus erythematosus (SLE) and psoriasis. Although advanced therapies have improved HS outcomes, many patients continue to experience suboptimal control, particularly when managing concurrent...
Atopic dermatitis (AD) is a chronic inflammatory skin disorder with rising prevalence worldwide. Its pathogenesis involves a complex interplay between genetic predisposition, skin barrier dysfunction, and immune dysregulation. Environmental exposures, including allergens and pollutants, are well-recognized triggers of disease activity. Increasing attention is now being directed...
Introduction Biologics have revolutionized the treatment of moderate-to-severe atopic dermatitis (AD), with dupilumab, an anti-interleukin-4Rα monoclonal antibody, showing notable clinical efficacy. However, some patients achieve rapid and profound improvement—termed super responders (SRs), while others respond poorly. This study aimed to identify SRs to dupilumab in patients...
Artificial intelligence (AI) has profoundly impacted various medical fields, including dermatology, which is to a large extent an image-based discipline. Initially applied in general dermatology, AI has expanded into aesthetic dermatology, where it assists in integrating objective approaches with the aesthetic judgment of dermatologists. This review explores the role of AI in...
Introduction Chronic spontaneous urticaria (CSU) is characterized by itchy wheals/hives and/or angioedema lasting longer than 6 weeks. Herein, we describe patients’ perspectives from the global Urticaria Voices study reporting treatment patterns, disease burden, treatment satisfaction, and expectations. Methods This global, cross-sectional online survey was conducted from...
Introduction Although skin diseases are a significant public health concern, epidemiological data for Poland is still lacking. This study aimed to fill this scientific gap by analyzing the prevalence of skin diseases and associated risk factors in the Polish population. Methods A cross-sectional study was conducted using data from the National Healthy Skin Test (2023), an online...
Basal cell carcinoma (BCC) is the most common skin cancer, primarily affecting the head and neck region. This study aimed to evaluate the characteristics of BCCs in different facial areas using polarized dermoscopy (PD) and ultraviolet-induced fluorescence dermoscopy (UVFD). BCCs were examined using a Dermlite DL5 dermatoscope in polarized and UVFD modes. The tumors were...
Palmoplantar pustulosis (PPP) is a chronic, relapsing disease with sterile pustules involving the palms and soles. The pathogenesis of PPP remains unclear and there is currently no standard treatment. We present three cases of recalcitrant PPP treated with topical 2% crisaborole cream in our clinic from October 2024 to February 2025. All of the patients had received skin biopsy...
Despite significant progress observed in the treatment of atopic dermatitis (AD), a considerable number of patients with severe disease are undertreated and have inadequate symptom control. This may be due to several reasons, such as underestimation of the implications of the disease on patients, families, and society, as well as inconsistent access to effective treatment. The...
Atopic dermatitis (AD) is a highly prevalent disease in Canada with significant patient burden. Treatment guidance for topical therapy (the mainstay of AD management), with particular consideration of emerging treatments, may further improve patient care. Here, we aim to provide healthcare professionals with AD treatment recommendations from the perspective of 10 Canadian...